Editas Medicines has signed a $238 million biobucks pact to combine Genevant Science’s lipid nanoparticle (LNP) tech with the ...

Interius’s breakthrough technology allows precise targeting of gene therapies to specific cells via intravenous administration," said Interius President and CEO, Phil Johnson, M.D. "This milestone ...

In April 2024, Prime Medicine received the go-ahead from the FDA to initiate a phase I/2 trial with PE-based PM359, an ex vivo gene therapy to treat CGD (chronic granulomatous disease).

Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...

That is why the company is also working on gene therapy and ex vivo gene-edited cell therapy. “If you’re working in gene editing, you can also work in gene therapy, because you already know a ...

Editas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with ...

Intellia Therapeutics is pioneering in vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In vivo gene editing for increased accessibility to CRISPR-based therapies Existing gene therapies that use non-viral vectors for therapeutic delivery typically require ex vivo editing. A patient’s ...

Gene therapy and gene editing are on the cutting ... CRISPR-based gene-editing technology to develop both in vivo and ex vivo cancer cell therapies. Analyst Graham Parry says Sanofi is an ...

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...

快科技9月25日消息，2024中国网球公开赛前夕，郑钦文身穿印有vivo商标的球服参加赛前新闻发布会的照片引起热议，许多网友猜测郑钦文要代言vivo了。